Topics:

Lung Cancer

Lung Cancer

Epidermal growth factor receptor tyrosine kinase inhibitors may not be the best option for some patients with nonsmall cell lung cancer, but an ALK inhibitor, crizotinib, proves a winner.

GlaxoSmithKline has stopped a phase III trial of a novel lung cancer immunotherapeutic agent, after determining that it may not be possible to identify which genetic subgroups may benefit from the treatment.

A biomarker and five clinical factors help to predict which patients with nonsmall-cell lung cancer are at high risk for lung inflammation after radiotherapy.

The new ALK inhibitor certinib showed strong antitumor activity in a phase I expansion study of patients with advanced non-small-cell lung cancer (NSCLC).

In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.

In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.

Combining both cetuximab and bevacizumab with platinum-based chemotherapy showed strong efficacy in a phase II trial of patients with advanced non-small-cell lung cancer.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.